Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue ...

Sales at Abbott Laboratories' diagnostics unit dropped in the second quarter as demand for COVID-19 tests slumped. The company beat profit and sales estimates on strong sales of its medical devices.

Abbott is the name behind many well-known products.

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...